Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity Disorder,Journal of Child and Adolescent Psychopharmacology

当前位置： X-MOL 学术 › J. Child Adolesc. Psychopharmacol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity Disorder
Journal of Child and Adolescent Psychopharmacology ( IF 1.9 ) Pub Date : 2021-06-16 , DOI: 10.1089/cap.2020.0142
Ann C Childress ₁ , Scott H Kollins ₂ , Andrew J Cutler ₃ , Andrea Marraffino ₄ , Carolyn R Sikes _{5,

6}

Affiliation

Objective: To examine the efficacy, safety, and tolerability of methylphenidate extended-release orally disintegrating tablets (MPH XR-ODT) for the treatment of attention-deficit/hyperactivity disorder (ADHD) during the open-label dose-optimization/stabilization period of a phase 3 laboratory classroom study.

中文翻译：